Lattice Biologics Ltd. (TSXV:LBL), a biotech stock, climbed after announcing that it has begun enrolling patients in its Phase 1 clinical trial for the treatment of SARS
A pending clinical trial for treating a COVID-19 related illness lifted shares of a Canada-listed biotech stock Tuesday. Here’s some small stocks making big moves on Tuesday, March 17, 2020 (as of 11:30 am EST):
Lattice Biologics Ltd. (TSXV:LBL), a Canada-listed biotech stock, surged 56% to $0.14 on Tuesday after announcing that it has begun enrolling patients in its Phase 1 clinical trial to address safety and efficacy of its stem cell technology, AmnioBoost, for the treatment of severe acute respiratory syndrome (SARS) related to COVID-19 infection.
As well, shares of Visionstate Corp. (TSXV:VIS) gained 33% to $0.065 as the Company said it has seen a marked uptick of inquiries about its WANDA IoT solution in the wake of the coronavirus outbreak. WANDA is a smart tablet that is mounted at the entrance of public restrooms and monitors cleaning activities to ensure that those efforts are compliant with required procedures in order to meet high standards of cleanliness.
Elixxer Ltd. (TSXV:ELXR), meanwhile, reported that its Italian pharmaceutical partner, Freia Farmaceutici, has successfully launched its topical hand sanitizer, Dermogel, in Italy with their initial block of 10,000 units. Elixxer stock moved up 40% to $0.035 following the announcement.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
Lattice Biologics Ltd. (TSXV:LBL), a Canada-listed biotech stock, surged 56% to $0.14 on Tuesday after announcing that it has begun enrolling patients in its Phase 1 clinical trial to address safety and efficacy of its stem cell technology, AmnioBoost, for the treatment of severe acute respiratory syndrome (SARS) related to COVID-19 infection.
, on Tuesday.){kind=link}